{
  "emaEpar": [
    {
      "activeSubstance": "dacomitinib monohydrate",
      "conditionIndication": "Vizimpro, as monotherapy, is indicated for the first-line treatment of adult patients with locally advanced or metastatic non small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) activating mutations.",
      "inn": "dacomitinib",
      "marketingAuthorisationDate": "2019-04-02 00:00:00",
      "marketingAuthorisationHolder": "Pfizer Europe MA EEIG",
      "medicineName": "Vizimpro",
      "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/vizimpro"
    }
  ],
  "fdaDrugLabel": [
    {
      "brand": "Vizimpro",
      "indication": "1 INDICATIONS AND USAGE VIZIMPRO is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test [see Dosage and Administration (2.1) ] . VIZIMPRO is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test. ( 1 )",
      "manufacturer": "Pfizer Laboratories Div Pfizer Inc",
      "splSetId": "4ab27d2f-e385-4e9c-b324-fa69c10b855a"
    },
    {
      "brand": "Vizimpro",
      "indication": "1 INDICATIONS AND USAGE VIZIMPRO is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test [see Dosage and Administration (2.1) ] . VIZIMPRO is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test. ( 1 )",
      "manufacturer": "U.S. Pharmaceuticals",
      "splSetId": "90da33c1-5689-4b4d-a2b5-377e1057a843"
    }
  ],
  "id": "Dacomitinib",
  "nciThesaurus": {
    "casRegistry": "1042385-75-0",
    "chebiId": "",
    "chemicalFormula": "C24H25ClFN5O2.H2O",
    "definition": "A highly selective, orally bioavailable small-molecule inhibitor of the HER family of tyrosine kinases with potential antineoplastic activity. Dacomitinib specifically and irreversibly binds to and inhibits human Her-1, Her-2, and Her-4, resulting in the proliferation inhibition and apoptosis of tumor cells that overexpress these receptors.",
    "fdaUniiCode": "5092U85G58",
    "identifier": "C53398",
    "preferredName": "Dacomitinib",
    "semanticType": "Pharmacologic Substance",
    "subclassOf": [
      "C129825",
      "C2167"
    ],
    "synonyms": [
      "(2E)-N-(4-((3-Chloro-4-Fluorophenyl)Amino)-7-Methoxyquinazolin-6-yl)-4-Piperidin-1-ylbut-2-Enamide",
      "DACOMITINIB",
      "Dacomitinib",
      "EGFR Inhibitor PF-00299804",
      "PF-00299804",
      "PF-00299804-03",
      "PF-299804",
      "Vizimpro"
    ]
  }
}